These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 29908870)

  • 1. Current and emerging therapies for corneal neovascularization.
    Roshandel D; Eslani M; Baradaran-Rafii A; Cheung AY; Kurji K; Jabbehdari S; Maiz A; Jalali S; Djalilian AR; Holland EJ
    Ocul Surf; 2018 Oct; 16(4):398-414. PubMed ID: 29908870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corneal neovascularization and biological therapy.
    Voiculescu OB; Voinea LM; Alexandrescu C
    J Med Life; 2015; 8(4):444-8. PubMed ID: 26664467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model.
    Mirabelli P; Peebo BB; Xeroudaki M; Koulikovska M; Lagali N
    Exp Eye Res; 2014 Aug; 125():118-27. PubMed ID: 24933712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current treatments for corneal neovascularization].
    Benayoun Y; Petellat F; Leclerc O; Dost L; Dallaudière B; Reddy C; Robert PY; Salomon JL
    J Fr Ophtalmol; 2015 Dec; 38(10):996-1008. PubMed ID: 26522890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for corneal neovascularization: a review.
    Gupta D; Illingworth C
    Cornea; 2011 Aug; 30(8):927-38. PubMed ID: 21389854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corneal neovascularization: updates on pathophysiology, investigations & management.
    Sharif Z; Sharif W
    Rom J Ophthalmol; 2019; 63(1):15-22. PubMed ID: 31198893
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent drug therapies for corneal neovascularization.
    Liu X; Wang S; Wang X; Liang J; Zhang Y
    Chem Biol Drug Des; 2017 Nov; 90(5):653-664. PubMed ID: 28489275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corneal neovascularization.
    Nicholas MP; Mysore N
    Exp Eye Res; 2021 Jan; 202():108363. PubMed ID: 33221371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-based antiangiogenic applications for corneal neovascularization.
    Liu S; Romano V; Steger B; Kaye SB; Hamill KJ; Willoughby CE
    Surv Ophthalmol; 2018; 63(2):193-213. PubMed ID: 29080632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of corneal neovascularization: Current and emerging therapeutic approaches.
    Wu D; Chan KE; Lim BXH; Lim DK; Wong WM; Chai C; Manotosh R; Lim CHL
    Indian J Ophthalmol; 2024 May; 72(Suppl 3):S354-S371. PubMed ID: 38648452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Treatments for Corneal Angiogenesis.
    Syed ZA; Dana R
    Int Ophthalmol Clin; 2017; 57(4):31-38. PubMed ID: 28885245
    [No Abstract]   [Full Text] [Related]  

  • 12. Matrix revolution: molecular mechanism for inflammatory corneal neovascularization and restoration of corneal avascularity by epithelial stem cell transplantation.
    Ma DH; Chen HC; Lai JY; Sun CC; Wang SF; Lin KK; Chen JK
    Ocul Surf; 2009 Jul; 7(3):128-44. PubMed ID: 19635246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
    Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
    Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limbal stem cell deficiency and corneal neovascularization.
    Lim P; Fuchsluger TA; Jurkunas UV
    Semin Ophthalmol; 2009; 24(3):139-48. PubMed ID: 19437349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subconjunctival bevacizumab for corneal neovascularization.
    Zaki AA; Farid SF
    Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization.
    Lai CM; Brankov M; Zaknich T; Lai YK; Shen WY; Constable IJ; Kovesdi I; Rakoczy PE
    Hum Gene Ther; 2001 Jul; 12(10):1299-310. PubMed ID: 11440623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Available Therapeutic Options for Corneal Neovascularization: A Review.
    Drzyzga Ł; Śpiewak D; Dorecka M; Wyględowska-Promieńska D
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Horizons in therapy for corneal angiogenesis.
    Maddula S; Davis DK; Maddula S; Burrow MK; Ambati BK
    Ophthalmology; 2011 Mar; 118(3):591-9. PubMed ID: 21376242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.
    Barry Z; Park B; Corson TW
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current trends in the management of corneal neovascularization.
    Rangu N; Dang DH; Riaz KM
    Curr Opin Ophthalmol; 2024 Jul; 35(4):329-342. PubMed ID: 38813739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.